VivoSim Labs Prices $4M Private Placement at $0.85 and Amends Armistice Warrants Down to $0.85

summarizeSummary

VivoSim Labs raised $4 million in a private placement at $0.85 per share, a premium to its current $0.55 price, but the deal includes warrants that could double the share count and an amendment to existing warrants that slashes the exercise price from $9.60 to $0.85, adding significant dilution risk.

check_boxKey Events · Financing and Capital Events · VIVS

• $4M Private Placement Priced at $0.85

  VivoSim sold 4,705,883 pre-funded warrants and an equal number of common warrants at a combined $0.85 per share, raising $4 million before fees. The pre-funded warrants are exercisable immediately at $0.001, while the common warrants have a $0.85 exercise price and require stockholder approval.

• Armistice Warrant Amendment Slashes Exercise Price

  Existing warrants held by Armistice Capital for 520,833 shares had their exercise price cut from $9.60 to $0.85 and their term extended to five years post-stockholder approval, aligning them with the new financing terms.

• Potential Dilution Exceeds 400% of Outstanding Shares

  The 4.7 million pre-funded warrant shares plus 4.7 million common warrant shares, combined with the amended Armistice warrants, could add over 9.9 million shares — more than double the current outstanding — if all warrants are exercised.

• Stockholder Approval Required Within 75 Days

  The company must hold a stockholder meeting within 75 days to approve the common warrants and the Armistice warrant amendment, with the board recommending approval and management voting in favor.

auto_awesomeAnalysis · VIVS · Life Sciences

A micro-cap biotech with a going-concern warning and a stock near its 52-week low, VivoSim Labs raised $4 million in a private placement priced at $0.85 per share — a premium to the current $0.55 price. The deal includes pre-funded warrants and common warrants, effectively doubling the potential share count to 9.4 million shares. Critically, the company also amended existing Armistice Capital warrants, slashing the exercise price from $9.60 to $0.85 and extending the term, which could bring in additional cash if exercised but adds to the overhang. The placement agent fee is 6.5%, and the company must seek stockholder approval for the common warrants and the Armistice amendment within 75 days. While the capital extends the cash runway, the dilutive structure and the warrant repricing signal desperation and could pressure the stock further.